

Curriculum Vitae

Arianna Carolina Rosa, PhD, PharmD



PERSONAL INFORMATION

Family name, First name: **ROSA, Arianna Carolina:**

Research ID: **C-5250-2015**

Date of birth: **25/06/1977**

Nationality: **Italian**

URL for web site:

http://www.dstf.unito.it/unitoWAR/page/dipartimenti3/D025/D025_il_dipartimento2?path=/BEA%20Repository/4830057

EDUCATION

21/02/2007 PhD in Drug Science; Faculty of Pharmacy, University of Turin, Italy

18/07/2003 Master Degree in Pharmacy Faculty of Pharmacy, University of Turin, Italy

CURRENT POSITION(S)

21th December 2020-present: Associate Professor in Pharmacology, Dept. of *Scienza e Tecnologia del Farmaco*, University of Turin, Italy.

PREVIOUS POSITIONS

29th December 2015- 1st July 2016: Visitor Scientista the School of Biological & Biomedical Sciences, Science Park, Durham University (UK) within the World Wide Style 2 Program of the University of Turin.

21th March 2011 - 7th April 2011 Visitor Scientist at the School of Biological & Biomedical Sciences, Science Park, Durham University (UK) within a COST Action BM0806 Short Term Scientific Mission (STSM), under the supervision of Dr. Paul L Chazot (Vice Chair), with a project entitled "Expression analysis and localization of H₄ receptors in the kidney"

2006-21th December 2020: Lecturer (Ricercatore Confermato) in Pharmacology, Dept. of *Scienza e Tecnologia del Farmaco*, ex-Faculty of Pharmacy, University of Turin, Italy

FELLOWSHIPS AND AWARDS

2015: Research Fellowship within the World Wide Style 2 Program of the University of Turin

2013: Early Stage Research Award received from COST Action BM0806 for the contribution "The histamine H₄ receptor in the kidney" Final Conference of COST Action BM0806 – Advance in Histamine H₄R Research (21-23 March 2013, Cape Sounion, Athens Greece)

2012: Early Stage Research Award received from COST Action BM0806 for the contribution "The histamine H₄ receptor is overexpressed in the kidney of diabetic rats" presented at the European Histamine Research Society 41st Annual Meeting held jointly with COST Action BM0806 (2-5 May 2012, Belfast)

2009/2010/2011/2012/2013/2014: "SIF-Farmaci in evidenza" and "SIF-Farmacogenetica" collaborators Award received from The Italian Society of Pharmacology, Italy

2006: Top cited research paper 2006 for the article "Modulation of the oxidative stress and inflammatory response by PPAR- γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion" *Eur J Pharmacol* 2006; 530: 70-80

2003: three year PhD scholarship from University of Turin, Italy

SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS

2013-present: External Examiner of 3 Postdoctoral Fellows of the University of Florence, Florence, Italy

2014-2015: Supervisor of 1 Postdoctoral Fellow, Dept. of *Scienza e Tecnologia del Farmaco*, University of Turin, Italy

2013-2016: Scientific supervisor of 1 PhD Student, Dept. of *Scienza e Tecnologia del Farmaco*, University of Turin, Italy

2013-present: Supervisor of 2 Master Students in Pharmaceutical Chemistry and Technology, more than 6 Master Students in Pharmacy, 3 Master Students in Medical Biotechnology and 1 Master Student in Cellular and Molecular Biology, University of Turin, Italy;

2006-present: Supervisor of more than 20 Bachelor Degree Students on Medical Sales Representative, 3 Bachelor Degree Students on Nursing registered Degree, and 3 Bachelor Degree Students in Biotechnology University of Turin, Italy

TEACHING ACTIVITIES

2022/2023-present Teacher of “Toxicology” Master Degree on Pharmaceutical Chemistry and Technology, University of Turin, Italy

2020/2021-present Teacher of “Experimental Pharmacology” Master Degree on Pharmacy, University of Turin, Italy

2018/2019-present Teacher of “Internship in pharmacology of autacoids” Master Degree on Medical Biotechnology, University of Turin, Italy

2017/2018-present Teacher of “Toxicology and pharmacovigilance” Master Degree on Pharmacy, University of Turin, Italy

2016/2017-present Teacher of “Pharmacovigilance” School for clinical Pharmacist, University of Turin, Italy

2016/2017-present Academic Referent of “Monitoring for adverse reactions and evaluation of the adverse reporting form” School for clinical Pharmacist, University of Turin, Italy

2016/2017-present Academic Referent of “Monitoring for adverse reactions from use of medical devices” School for clinical Pharmacist, University of Turin, Italy

2016/2017-present Academic Referent of “On-site patient counseling activities of dispensing of drugs I” School for clinical Pharmacist, University of Turin, Italy

2016/2017-present Academic Referent of “On-site patient counseling activities of dispensing of drugs II” School for clinical Pharmacist, University of Turin, Italy

2016/2017: Teacher of “Pharmacological research: results and perspectives ”in the context of I level Master in "Endocrinology, Diabetology and Metabolic Diseases: Module 4 - Research and clinical-assistance experimentation ", Department of Medical Sciences, University of Turin, Turin, Italy

1st October 2011-30th September 2015: Teacher of “Pharmacological basis of the main protocols therapeutics used for the treatment of colorectal cancer” Advanced Course in Department Pharmacist, Faculty of Pharmacy, University of Turin, Italy

1st October 2011-30th September 2015: Teacher of “Use of colloid drugs with particular reference to the use of albumin” Advanced Course in Department Pharmacist, Faculty of Pharmacy, University of Turin, Italy

2012/2013 present Teacher of the modules “Pharmacology I and Pahrmacology II” Nursing registered Degree, University of Turin, Italy

2011-2012/2012-2013/2013-2014/2014-2015 Teacher of “Pharmacovigilance insight” Master Degree on Pharmacy, University of Turin, Italy

2012-2013/2013-2014 Teacher of “Pharmacoutilization” School for clinical Pharmacist, University of Turin, Italy

30/01/2013-1/02/2013 Expert for the module “In vitro models to evaluate leukocyte trafficking”, COST BM0806 Training School Pharmacological models of inflammatory and immunological disorders, Trinity College, Dublin, Ireland

January 2011 Teacher of “Molecular basis of the physio-pharmacology of metabolic diseases” for the Ph.D. Program in Pharmaceutical and Biomolecular Sciences of PhD School of Natural Sciences and Innovative Technologies, Dept. of *Scienza e Tecnologia del Farmaco*, University of Turin, Italy

2010-2011/2011-2012 Teacher of “Pharmacology and Therapeutics” and “Toxicology and Pharmacovigilance”, Degree on Medical Sales Representative, Faculty of Pharmacy, University of Turin, Italy

INSTITUTIONAL RESPONSIBILITIES

October 2021-present: Secretary of the Master Degree on Pharmacy, University of Turin, Italy

2019-present: Member of the Board of Tutors of the Doctoral School in Pharmaceutical Sciences e Biomolecular, University of Turin, Italy

2018-2021: Member of the Research Committee, Dept. of *Scienza e Tecnologia del Farmaco*, University of Turin, Italy

2013-2015: Member of the Education Committee, Dept. of *Scienza e Tecnologia del Farmaco*, University of Turin, Italy

September 2014 Organizer of the Internal Seminar entitled *Histamine H4 receptor: potential new target for itch and neuropathic pain?* of Paul L Chazot for the Ph.D. Program in Pharmaceutical and Biomolecular Sciences of PhD School of Natural Sciences and Innovative Technologies, Dept. of *Scienza e Tecnologia del Farmaco*, University of Turin, Italy

2009-present: Students with disabilities Contact Person, Dept. of *Scienza e Tecnologia del Farmaco*, University of Turin, Italy

2006-present: Graduate Student Advisor, Dept. of *Scienza e Tecnologia del Farmaco*, ex-Faculty of Pharmacy, University of Turin, Italy, University of Turin, Italy

COMMISSIONS OF TRUST (if applicable)

September 2022-present: Elected Member of the Council of the European Histamine Research Society

2019-present: Member of the Doctoral School of the University of Torino, Ph.D. Program in Pharmaceutical and Biomolecular Sciences

May 2015-June 2018: Elected Member of the Council of the European Histamine Research Society

2011-2012: Team Leader for a working group for the fulfilment of a Drug Handbook 2012

2008-present: Invited author for the Italian Journal "Punto Effe" writing articles on pharmacological issues

2008-Novembre 2018: Team Leader for the monthly section "Dipositivi medici in evidenza" on the on-line fortnightly newsletter "SIF-Farmaci in evidenza" published by the Italian Society of Pharmacology (<http://www.sifweb.org>)

2007-Novembre 2018: Reviewer for the on-line fortnightly newsletter "SIF-Farmaci in evidenza" published by the Italian Society of Pharmacology (<http://sifweb.org>)

MEMBERSHIPS OF SCIENTIFIC SOCIETIES (if applicable)

2017-present: Member of the European Diabetic Nephropathy Study Group

2012-present: Member of the European Association for the Study of Diabetes

2011-present: Member of the European Histamine Research Society

2011-2013: Active ESR Member of COST Action BM0806, joining the Working Group 2 - Physiological and pathophysiological importance of the H4R systems. www.histamineresearch.com

2005-present: Member of The Italian Society of Pharmacology

EDITORIAL ACTIVITY

2019-present: Guest Editor of the Research Topic: The Challenge of New Therapeutic Approaches for Unmet Therapeutic Needs. *Frontiers in Pharmacology, Experimental Pharmacology and Drug Discovery* Section (17 articles) and volume II (ongoing)

November 2016-present: Editorial Member of *Source Journal of Pharmaceutical Sciences*

October 2016-present: Editorial Member of *EC Pharmacology and Toxicology* journal

October 2016-present: Editorial Member of *Archives of Pathology and Clinical Research*

July 2016: Co-Editor of *Infamm Res* for the Special Issue The European Histamine Research Society 45th Annual Meeting, May 11-14, 2016 Florence Italy; Vol. 65 (suppl 1): S1-S53; 2016

MAJOR COLLABORATIONS

Dr. PL Chazot, Topic: histamine in diabetic nephropathy, School of Biological and Biomedical Sciences and Wolfson Research Institute, Durham University, UK

Dr. A. Pini, Topics: histamine in diabetic nephropathy and in lung fibrosis, new ocular formulation for corneal disease, Dept. Clinical and Experimental Medicine, Anatomy and histology section, University of Florence, Italy

Prof. G. Camussi and Dr. C. Grange, Topic: diabetic nephropathy models, Dept. Medical Science, University of Turin, Italy

Dr. R.L. Thurmond, Topic: histamine in diabetic nephropathy, Janssen Research and Development, LLC, USA.

Dr. S. Liu, Topic: histamine H₃R receptor in diabetes complications, Ziarco Pharma, US

Prof. E. Masini, Topic: histamine and lung fibrosis, Dept. NEUROFARBA, Pharmacology Section, University of Florence, Italy

Prof. M. Ennis, Topic: lung diseases, School of Medicine, Dentistry and Biomedical Sciences and Centre for Infection and Immunity, Queen's University, Belfast, UK

Dr. L. Filippi, Topic: New ocular formulation for corneal disease, *Terapia Intensiva Neonatale, Azienda Ospedaliera Universitaria Meyer*, Florence, Italy

Prof. R. Cavalli, Topic: New ocular formulation for corneal disease and development of in vitro model to assess drug oral bioavailability; Dept. of *Scienza e Tecnologia del Farmaco*, University of Turin, Italy

RESEARCH SUPPORTS

Grant for Internationalization – GFI 2022 CoPI

Grant progetti Ateneo/CSP 2012

University of Turin Fund 2013

University of Turin Fund 2014

University of Turin Fund 2015

Grant Richieste Ordinarie 2015 from CRT Foundation; CoI

University of Turin Fund 2016

University of Turin Fund 2017

University of Turin Fund 2018

University of Turin Fund 2019

University of Turin Fund 2020

University of Turin Fund 2021

I have collaborated to the following research project:

Regione Piemonte, Italy 2009 “Sindrome metabolica e rischio di ischemia renale: potenzialità terapeutiche di agonisti selettivi dei recettori PPARbeta/delta”

Regione Piemonte, Italy 2008 za renale acuta: valutazione di efficacia di nuove terapie in modelli sperimentali”

Italian Ministry of Education, University and Research, PRIN 2007 “Sindrome metabolica come fattore di rischio per l'ischemia-riperfusion: fasi sperimentali per nuove strategie terapeutiche contro il danno da infiammazione e da stress ossidativo”

Italian Ministry of Education, University and Research, PRIN 2004 “Studio delle alterazioni biomolecolari e dei profili di espressione genica nel carcinoma coloretale e pancreatico: identificazione di possibili elementi prognostici e bersagli terapeutici nel sistema degli eicosanoidi e dei cannabinoidi”

Regione Piemonte, Italy 2002 “Studio di fattori che influenzano la trasformazione colon in epitelio adenomatoso”

I have extensive experience in studying receptors as new pharmacological targets. In particular, I was involved in projects probing the effects of celecoxib distinct from COX-2 inhibition; the neuroprotective effects of PPARgamma agonists on *in vivo* and *in vitro* models of ischemic injury. More recently, I have focused on the kidney as the end-organ of metabolic disease such as diabetes. In these years I worked also on models of cell-cell adhesion. During these past several years, I have also started important activity on drug information that gives me the opportunity to further develop my professional profile and the necessary skills to be a team leader by coordinating the monthly section “Dispositivi medici in evidenza” of the on-line fortnightly newsletter “SIF-Farmaci in evidenza” for the Italian Society of Pharmacology (<http://www.sifweb.org>), and being the team leader of a working group for the fulfillment of a Drug Handbook 2012. My interest in renoprotective pharmacological strategies led me to gain insight into the pathophysiological role of histamine receptors in the kidney. In 2011, I joined the COST Action BM0806 Working Group 2 - Physiological and pathophysiological importance of the H₄R systems (Leader: Prof. E Masini; University of Florence) as an Early Stage Researcher, performing an STSM at the University of Durham, under the supervision of Dr. Paul L Chazot. Here I broadened my experience and further developed

my professional profile as Assistant Professor in Pharmacology, integrating my methodological know-how with experimental techniques such as immunohistochemistry and the production of polyclonal antibodies. During this STSM, I obtained exciting pilot data suggesting a possible role for H4R in diabetic nephropathy which provides a strong rationale for further investigation in this field. These data were awarded a COST Action BM0806 Early Stage Research Award at the EHRS 41st Annual Meeting held jointly with COST Action BM0806 (2-5 May 2012, Belfast). The relevance of these data allowed me to receive funding, as a PI, by Ateneo/CSP2012, with the project “H4 Histamine Receptor As A New Pharmacological Target For The Treatment Of Diabetic Nephropathy (HISDIAN)”. Thanks to this project I achieved novel data on the possible role for H4R in diabetic nephropathy (awarded with an “Early Stage Researcher Award” at the “Final Conference of COST Action BM0806; Advances in Histamine H4R Research”; Cape Sounion, Athens Greece 21-23 March 2013) and on the presence of H3R. These results led me to develop in vivo modeling of diabetic nephropathy, as well as specific cellular modeling for the study of the glomerular filtration barrier, with the use of human podocytes in one-dimensional and tranwell cultures, and tubular epithelium. My interest in the modeling of physiological barriers led me to develop also in vitro transwell model of the intestinal barrier to predict the bioavailability of new drug formulations. Very recently, my expertise converged also in a collaboration with Prof. Elisa Benetti, to study the role of the orphan receptor GPR21 on both glucose uptake from liver cells and macrophage polarization. In these years, I developed many new interactions and skill exchanges; I delivered a lecture session at the COST BM0806 Training School Pharmacological models of inflammatory and immunological disorders (30/01- 1/02/2013 Trinity College, Dublin) entitled “In vitro models to evaluate leukocyte trafficking” and I established continuative national and international collaborations. In particular, I established international multidisciplinary collaborations for the study of histamine in diabetic nephropathy which includes Dr. PL Chazot (President of the EHRS society), Prof. G. Camussi, and Dr. C. Grange of the Department of Internal Medicine, Centre for Molecular Biotechnology and Centre for Research in Experimental Medicine (CeRMS), University of Turin, Prof. A. Pini Dept. Clinical and Experimental Medicine, Anatomy and Histology section, University of Florence, and Dr. Rob Thurmond (Lead H4R drug developer, J&J Janssens, USA). I get the National Habilitation as Associate Professor on April the 12th 2017, and on December 2021 I was appointed of the qualification of Associate Professor at the University of Turin, Italy.

PEER-REVIEWED ORIGINAL PUBLICATIONS

Boscaro V, Rivoira M, Sgorbini B, Bordano V, Dadone F, Gallicchio M, Pons A, Benetti E, **Rosa AC**. Evidence-Based Anti-Diabetic Properties of Plant from the Occitan Valleys of the Piedmont Alps. *Pharmaceutics*. 2022 Nov 3;14(11):2371. doi: 10.3390/pharmaceutics14112371.

Bordano V, Kinsella GK, Cannito S, Dianzani C, Gigliotti CL, Stephens JC, Monge C, Bocca C, **Rosa AC**, Miglio G, Dianzani U, Findlay JBC, Benetti E. G protein-coupled receptor 21 in macrophages: An in vitro study. *Eur J Pharmacol*. 2022 Jul 5; 926:175018. doi: 10.1016/j.ejphar.2022.175018. Epub 2022 May 7.

Rosa AC, Nardini P, Sgambellone S, Gurrieri M, Spampinato SF, Dell’Accio A, Chazot PL, Obara I, Liu WL, Pini A. CNS-Sparing Histamine H3 Receptor Antagonist as a Candidate to Prevent the Diabetes-Associated Gastrointestinal Symptoms. *Biomolecules*. 2022; 12(2):184. <https://doi.org/10.3390/biom12020184>

Verta R, Gurrieri M, Borga S, Benetti E, Pollicino P, Cavalli R, Thurmond RL, Chazot PL, Pini A, **Rosa AC**, Grange C. The interplay between histamine h4 receptor and the kidney function: The lesson from h4 receptor knockout mice. *Biomolecules*. 2021 Oct 15;11(10):1517. doi: 10.3390/biom11101517

Kinsella GK, Cannito S, Bordano V, Stephens JC, **Rosa AC**, Miglio G, Guaschino V, Iannaccone V, Findlay JBC, Benetti E. GPR21 inhibition increases glucose-uptake in HepG2 cells. *Int J Mol Sci*. 2021 Oct 5;22(19):10784. doi: 10.3390/ijms221910784.

Rosa AC, Corsi D, Cavi N, Bruni N, Dosio F. Superoxide dismutase administration: A review of proposed human uses. *Molecules*. 2021 Mar 25;26(7):1844. doi: 10.3390/molecules26071844.

Rosa AC, Bruni N, Meineri G, Corsi D, Cavi N, Gastaldi D, Dosio F. Strategies to expand the therapeutic potential of superoxide dismutase by exploiting delivery approaches *Int J Biol Macromol*. 2021 Jan 31;168:846-865. doi: 10.1016/j.ijbiomac.2020.11.149.

Pini A, Fazi C, Nardini P, Calvani M, Fabbri S, Guerrini A, Forni G, La Marca G, **Rosa AC**, Filippi L. Effect of Beta 3 Adrenoreceptor Modulation on Patency of the Ductus Arteriosus. *Cells*. 2020 Dec 7;9(12):2625. doi: 10.3390/cells9122625

Appleton SL, Tannous M, Argenziano M, Muntoni E, **Rosa AC**, Rossi D, Caldera F, Scomparin A, Trotta F, Cavalli R. Nanosponges as protein delivery systems: Insulin, a case study. *Int J Pharm*. 2020 Nov 30;590:119888. doi: 10.1016/j.ijpharm.2020.119888.

Rosa AC, Mio M, Andreadou I, Sumbayev VV. Editorial: The Challenge of New Therapeutic Approaches for Unmet Therapeutic Needs. *Front Pharmacol*. 2020 Sep 30;11:01341. doi: 10.3389/fphar.2020.01341.

Benetti E, Liberto E, Bressanello D, Bordano V, **Rosa AC**, Miglio G, Haxhi J, Pugliese G, Balducci S, Cordero C. Sedentariness and Urinary Metabolite Profile in Type 2 Diabetic Patients, a Cross-Sectional Study. *Metabolites*. 2020 May 18;10(5):205. doi: 10.3390/metabo10050205.

Grange C*, Gurrieri M*, Verta R, Fantozzi R, Pini A, **Rosa AC**. Histamine in the kidneys: what is its the role in renal pathophysiology? *Br J Pharmacol* 2020;177(3):503-515. doi:10.1111/bph.14619

Cucci MA, Compagnone A, Daga M, Grattarola M, Ullio C, Roetto A, Palmieri A, **Rosa AC**, Argenziano M, Cavalli R, Simile MM, Pascale RM, Dianzani C, Barrera G, Pizzimenti S. Post-translational inhibition of YAP oncogene expression by 4-hydroxynonenal in bladder cancer cells. *Free Radic Biol Med*. 2019 Sep;141:205-219. doi: 10.1016/j.freeradbiomed.2019.06.009.

Verta R, Grange C, Gurrieri M, Borga S, Nardini P, Argenziano M, Ghè C, Cavalli R, Benetti E, Miglio G, Bussolati B, Pini A, **Rosa AC**. Effect of Bilastine on Diabetic Nephropathy in DBA2/J Mice. *Int J Mol Sci*. 2019 May 24;20(10). pii: E2554. doi: 10.3390/ijms20102554.

Pini A, Verta R, Grange C, Gurrieri M, **Rosa AC**. Histamine and diabetic nephropathy: an up today overview. *Clin Sci (Lond)*. 2019 Jan 3;133(1):41-54. doi: 10.1042/CS20180839

Rosa AC, Benetti E, Gallicchio M, Boscaro V, Cangemi L, Dianzani C, Miglio G. Analyzing Cysteine Site Neighbors in Proteins to Reveal Dimethyl Fumarate Targets. *Proteomics*. 2019 Jan 11:e1800301. doi: 10.1002/pmic.201800301.

Pini A, Grange C, Veglia E, Argenziano M, Cavalli R, Guasti D, Calosi L, Ghè C, Solarino R, Thurmond RL, Camussi G, Chazot PL, **Rosa AC**. Histamine H4 receptor antagonism prevents the progression of diabetic nephropathy in male DBA2/J mice. *Pharmacol Res*. 2018 Feb;128:18-28. doi: 10.1016/j.phrs.2018.01.002. Epub 2018 Jan 6.

Dianzani C, Foglietta F, Ferrara B, **Rosa AC**, Muntoni E, Gasco P, Della Pepa C, Canaparo R, Serpe L. Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in an in vivo model. *World J Gastroenterol*. 2017 Jun 21;23(23):4200-4210. doi: 10.3748/wjg.v23.i23.4200.

Veglia E*, Pini A*, Moggio A, Grange C, Premoselli F, Miglio G, Tiligada K, Fantozzi R, Chazot PL, **Rosa AC**. Histamine type 1-receptor activation by low dose of histamine undermines human glomerular slit diaphragm integrity. *Pharmacol Res*. 2016 Dec;114:27-38. doi: 10.1016/j.phrs.2016.10.011. Epub 2016 Oct 14.

Lucarini L*, Pini A*, **Rosa AC**, Lanzi C, Durante M, Chazot PL, Krief S, Schreeb A, Stark H, Masini E. Role of histamine H4 receptor ligands in bleomycin-induced pulmonary fibrosis. *Pharmacol Res*. 2016 Sep;111:740-8. doi:10.1016/j.phrs.2016.07.037. Epub 2016 Jul 27. PubMed PMID: 27475884.

Pini A, Obara I, Battell E, Chazot PL, **Rosa AC**. Histamine in diabetes: Is it time to reconsider? *Pharmacol Res*. 2016 Sep;111:316-24. doi:10.1016/j.phrs.2016.06.021. Epub 2016 Jun 22. PubMed PMID: 27343700.

Pini A*, Chazot PL*, Veglia E, Moggio A, **Rosa AC**. H3 receptor renal expression in normal and diabetic rats. *Inflamm Res*. 2015 May;64(5):271-3. doi:10.1007/s00011-015-0808-y. Epub 2015 Mar 7. PubMed PMID: 25745947.

Veglia E, Grange C, Pini A, Moggio A, Lanzi C, Camussi G, Chazot PL, **Rosa AC**. Histamine receptor expression in human renal tubules: a comparative pharmacological evaluation. *Inflamm Res*. 2015 Apr;64(3-4):261-70.

Rosa AC, Pini A, Lucarini L, Lanzi C, Veglia E, Thurmond RL, Stark H, Masini E. Prevention of bleomycin-induced lung inflammation and fibrosis in mice by naproxen and JNJ7777120 treatment. *J Pharmacol Exp Ther*. 2014 Nov;351(2):308-16. doi: 10.1124/jpet.114.215152. Epub 2014 Sep 2. PubMed PMID: 25185215.

Collino M, Rogazzo M, Pini A, Benetti E, **Rosa AC**, Chiazza F, Fantozzi R, Bani D, Masini E. Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury. *J Cell Mol Med*. 2013 Nov;17(11):1494-505. doi:10.1111/jcmm.12120. Epub 2013 Sep 20. PubMed PMID: 24079335; PubMed Central PMCID: PMC4117562.

Rosa AC, Fantozzi R. The role of histamine in neurogenic inflammation. *Br J Pharmacol*. 2013 Sep;170(1):38-45. doi: 10.1111/bph.12266. Review. PubMed PMID: 23734637; PubMed Central PMCID: PMC3764847.

Collino M, Rogazzo M, Pini A, Benetti E, **Rosa AC**, Fantozzi R, Bani D, Masini E. Acute treatment with relaxin attenuates the injury/dysfunction induced by renal ischemia/reperfusion injury. *Ital J Anat Embryol*. 2013;118(1 Suppl):74-6. PubMed PMID: 24640578.

Rosa AC, Grange C, Pini A, Katebe MA, Benetti E, Collino M, Miglio G, Bani D, Camussi G, Chazot PL, Fantozzi R. Overexpression of histamine H4 receptors in the kidney of diabetic rat. *Inflamm Res*. 2013 Apr;62(4):357-65. doi:10.1007/s00011-012-0587-7. Epub 2012 Dec 22.

Mondovi B, Fogel WA, Federico R, Calinescu C, Mateescu MA, **Rosa AC**, Masini E. Effects of amine oxidases in allergic and histamine-mediated conditions. *Recent Pat Inflamm Allergy Drug Discov*. 2013 Jan 1;7(1):20-34. Review. PubMed PMID: 22946464.

Miglio G, **Rosa AC**, Rattazzi L, Grange C, Camussi G, Fantozzi R. Protective effects of peroxisome proliferator-activated receptor agonists on human podocytes: proposed mechanisms of action. *Br J Pharmacol*. 2012 Oct;167(3):641-53. doi: 10.1111/j.1476-5381.2012.02026.x. PubMed PMID: 22594945; PubMed Central PMCID: PMC3449267.

Rosa AC, Rattazzi L, Miglio G, Collino M, Fantozzi R. Angiotensin II induces tumor necrosis factor- α expression and release from cultured human podocytes. *Inflamm Res*. 2012 Apr;61(4):311-7. doi: 10.1007/s00011-011-0412-8. Epub 2012 Jan 6. PubMed PMID: 22223068. IF 2,14 citation number (self-citation excluded): 5

Minelli R, Serpe L, Pettazzoni P, Minero V, Barrera G, Gigliotti C, Mesturini R, **Rosa AC**, Gasco P, Vivenza N, Muntoni E, Fantozzi R, Dianzani U, Zara GP, Dianzani C. Cholesteryl butyrate solid lipid nanoparticles inhibit the adhesion and migration of colon cancer cells. *Br J Pharmacol*. 2012 May;166(2):587-601. doi: 10.1111/j.1476-5381.2011.01768.x. PubMed PMID: 22049973; PubMed Central PMCID: PMC3417491.

Collino M, Benetti E, Miglio G, Castiglia S, **Rosa AC**, Aragno M, Thiemermann C, Fantozzi R. Peroxisome proliferator-activated receptor β/δ agonism protects the kidney against ischemia/reperfusion injury in diabetic rats. *Free Radic Biol Med*. 2011 Jan 15;50(2):345-53. doi: 10.1016/j.freeradbiomed.2010.10.710. Epub 2010 Nov 1. PubMed PMID: 21047550.

Miglio G, **Rosa AC**, Rattazzi L, Grange C, Collino M, Camussi G, Fantozzi R. The subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury. *Br J Pharmacol*. 2011 Jan;162(1):111-25. doi: 10.1111/j.1476-5381.2010.01032.x. PubMed PMID: 20840470; PubMed Central PMCID: PMC3012410.

Miglio G, **Rosa AC**, Rattazzi L, Collino M, Lombardi G, Fantozzi R. PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. *Neurochem Int.* 2009 Dec;55(7):496-504. doi: 10.1016/j.neuint.2009.05.001. Epub 2009 May 13. PubMed PMID: 19442697.

Miglio G, Rattazzi L, **Rosa AC**, Fantozzi R. PPARgamma stimulation promotes neurite outgrowth in SH-SY5Y human neuroblastoma cells. *Neurosci Lett.* 2009 Apr 24;454(2):134-8. doi: 10.1016/j.neulet.2009.03.014. Epub 2009 Mar 11. PubMed PMID: 19429070.

Gallicchio M, Benetti E, **Rosa AC**, Fantozzi R. Tachykinin receptor modulation of cyclooxygenase-2 expression in human polymorphonuclear leucocytes. *Br J Pharmacol.* 2009 Feb;156(3):486-96. doi: 10.1111/j.1476-5381.2008.00033.x. Epub 2009 Jan 16. PubMed PMID: 19154444; PubMed Central PMCID: PMC2697683.

Gallicchio M, Benetti E, **Rosa AC**, Fantozzi R. Substance P-induced cyclooxygenase-2 expression in polymorphonuclear cells. *Inflamm Res.* 2008;57 Suppl 1:S17-8. doi: 10.1007/s00011-007-0608-0. PubMed PMID: 18345509.

Gallicchio M, **Rosa AC**, Dianzani C, Brucato L, Benetti E, Collino M, Fantozzi R. Celecoxib decreases expression of the adhesion molecules ICAM-1 and VCAM-1 in a colon cancer cell line (HT29). *Br J Pharmacol.* 2008 Mar;153(5):870-8. Epub 2007 Dec 17. PubMed PMID: 18084318; PubMed Central PMCID: PMC2267284.

Dianzani C, Brucato L, Gallicchio M, **Rosa AC**, Collino M, Fantozzi R. Celecoxib modulates adhesion of HT29 colon cancer cells to vascular endothelial cells by inhibiting ICAM-1 and VCAM-1 expression. *Br J Pharmacol.* 2008 Mar;153(6):1153-61. Epub 2007 Dec 17. PubMed PMID: 18084316; PubMed Central PMCID: PMC2275462.

Gallicchio M, **Rosa AC**, Benetti E, Collino M, Dianzani C, Fantozzi R. Substance P-induced cyclooxygenase-2 expression in human umbilical vein endothelial cells. *Br J Pharmacol.* 2006 Mar;147(6):681-9. PubMed PMID: 16432508; PubMed Central PMCID: PMC1751347.

Collino M, Aragno M, Mastrocola R, Gallicchio M, **Rosa AC**, Dianzani C, Danni O, Thiemermann C, Fantozzi R. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. *Eur J Pharmacol.* 2006 Jan 13;530(1-2):70-80. Epub 2005 Dec 28. PubMed PMID: 16386242.

BOOK CHAPTERS

Pini A, Veglia E, **Rosa AC**. (2017) Histamine and the Kidney: In Vivo Animal Models. In: Tiligada E, Ennis M. (eds) *Histamine Receptors as Drug Targets. Methods in Pharmacology and Toxicology.* Humana Press, New York, NY

Pini A, Veglia E, Grange C, **Rosa AC**. (2017) Methodological Approaches to Study Histamine Pharmacology in the Kidney: From Cell Culture and Cell Imaging to Functional Assays and Electron Microscopy. In: Tiligada E, Ennis M. (eds) *Histamine Receptors as Drug Targets. Methods in Pharmacology and Toxicology.* Humana Press, New York, NY

INVITED SPEAKER

Rosa AC. Histamine Antagonists in the Kidney: May they Manage the Diabetic Nephropathy? 2nd International Conference on PharmScience Research & Development, Pharma R&D-2020, February 24-26, 2020, Los Angeles, CA, USA.

Rosa AC. Exploring the role of histamine in diabetic nephropathy. World Histamine Symposium (WHS2018) A satellite symposium of WCP2018 2nd Joint Symposium of European and Japanese Histamine Research Societies July 7-9, Kobe, Japan

Rosa AC. Histamine & diabetic nephropathy revisited. British Pharmacological Society (BPS) Pharmacology 2017, Queen Elizabeth II Conference Centre, London, 11-13 December 2017

Rosa AC. Histamine and diabetic nephropathy. School of Biological and Biomedical Sciences Seminar Durham University 15 March 2016

Rosa AC. Le differenze di genere nella valutazione clinica dei farmaci. Centro Regionale antidoping AOU San Luigi Gonzaga 27 November 2015

Rosa AC. I nuovi anticoagulanti orali. CISAF (collegio Indipendente Subalpino Arti Farmaceutiche) 27 November 2013

Rosa AC. Il diabete: un'epidemia in espansione. Comune di Pomaretto 6 December 2013.

Rosa AC. In vitro models to evaluate leukocyte trafficking. Training School: Pharmacological Models of Inflammatory and Immunological Disorders, Trinity College Dublin, Ireland 30/1-1/2/2013

Rosa AC Informazione indipendente dove reperirla. Corso CEFPAS Consumo dei farmaci e appropriatezza prescrittiva Caltanissetta 9-10 March 2009.

Rosa AC. Il diabete in farmacia. Corso ECM della Facoltà di Farmacia, Torino, 28 May 2009.

Rosa AC. Independent drug information as a tool for a better prescribing appropriateness: the experience of "Farmaci in evidenza" a newsletter from the Italian Society of Pharmacology. 34° Congresso Nazionale della Società Italiana di Farmacologia - Rimini 14- 17 October 2009.

CONFERENCE PROCEEDINGS

International Conference

Verta R, Gurrieri M, Borga S, Argenziano M, Nardini P, Cavalli R, Grange C, Pini A, **Rosa AC.** Effect of bilastine on the progression of diabetic nephropathy in DBA2/J mice. *48th European Histamine Research Society (HERS) Krakow, Poland, 15-18th May 2019*

Gurrieri M, Nardini P, Dell'Accio A, Ilona O, Liu S, **Rosa AC,** Pini A. CNS-sparing H3R antagonist as a candidate for the treatment of diabetes associated (gastro)intestinal symptoms. *48th European Histamine Research Society (HERS) Krakow, Poland, 15-18th May 2019*

Benetti E, Bordano V, Barutta F, Gruden G, Fedele C, **Rosa AC,** Klein T, Miglio G. DPP-4 release in human podocytes. *54th EASD Annual Meeting of the European Association for the Study of Diabetes, Berlin, Germany, 1 – 5 October 2018*

Verta R, Pini A, Gurrieri M, Grange C, Thurmond RL, **Rosa AC.** JNJ39758979 Preserves Renal Aquaporin Expression Balance in a Model of Diabetic Nephropathy. *47th European Histamine Research Society (HERS) Dublin, Ireland, 30th May-2nd June 2018*

Pini A, Verta R, Grange C, Thurmond RL, **Rosa AC.** Renal Function in the H4R Knockout Mouse. *47th European Histamine Research Society (HERS) Dublin, Ireland, 30th May-2nd June 2018*

Peira E, Chirio D, Sapino S, **Rosa AC,** Dianzani C, Canaparo R, Foglietta F, Carabelli V. SLN obtained by cold dilution of microemulsions as a promising quercetin-delivery system for oral administration in neurodegenerative disorders. *11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Granada, Spain, 19th – 22nd March 2018*

Rosa AC, Miglio G. Analysis of residue interaction networks to improve prediction of protein succination. *Pharmacology 2017, Queen Elizabeth II Conference Centre, London December 11-13, 2017*

Pini A, Veglia E, Grange C, Argenziano M, Cavalli R, Guasti D, Thurmond RL, Chazot PL, **Rosa AC**. H4R antagonism as a new therapeutic strategy for diabetic nephropathy: a first pre-clinical validation. *30th Annual General Meeting of the European Diabetic Nephropathy Study Group (EDNSG), Helsinki, Finland, May 19-20, 2017*

Battell E, **Rosa AC**, Chazot PL, Pini A, Liu WLS, Obara I, Novel peripheral histamine H3 receptor antagonist ZPL-868087 attenuates mechanical hypersensitivity in neuropathic pain in mice. *46th Annual Meeting of the European Histamine Research Society (EHRS), Amsterdam, The Netherlands, May 11-13, 2017*

Rosa AC, Pini A, Obara I, Sasse A, Sanchez- Jimenez F, Stark H, Masini E, Leurs R, Chazot PL. Histamine and diabetes: where we are and where are we going. *46th Annual Meeting of the European Histamine Research Society (EHRS), Amsterdam, The Netherlands, May 11-13, 2017*

Obara I, **Rosa AC**, Battell E, Pini A, Liu WLS, Chazot PL. Novel peripheral histamine H3 receptor antagonist ZPL-868087 attenuates mechanical hypersensitivity in neuropathic pain in mice. *Queen Elizabeth II Conference Centre London Pharmacology 2016, London December 13-15, 2016*

Rosa AC, Veglia E, Argenziano M, Cavalli R, Thurmond RL, Chazot PL, Pini A. A new hope for the treatment of diabetic nephropathy based on histamine H4R antagonism. *European Association for the Study of Diabetes 52nd Annual Meeting, Munich, Germany 12-16 September 2016*

Pini A, Veglia E, Grange C, Argenziano M, Cavalli R, Fantozzi R, Thurmond RL, Chazot PL, **Rosa AC**. JNJ 39758979 prevents the progression of diabetic nephropathy. *45th Annual Meeting of the European Histamine Research Society (EHRS), Florence, Italy, May 11-14, 2016*

Pini A, Chazot PL, **Rosa AC**. Parallel hierarchical intra-strain difference between the susceptibility to diabetic nephropathy and renal histamine receptor expression. *45th Annual Meeting of the European Histamine Research Society (EHRS), Florence, Italy, May 11-14, 2016*

Rosa AC. Antihistamine therapy for slit diaphragm integrity: an in vitro perspective. *Physiology, pathophysiology and future treatment options for diabetic complications, Hodgkin Huxley House, London, UK EC1R 3AW, December 7, 2015*

Veglia E, Pini A, Moggio A, Grange C, Fantozzi R, Chazot PL, **Rosa AC**. Histamine Affects the Glomerular Slit Diaphragm Integrity Through H1R. *44rd Annual Meeting of the European Histamine Research Society (EHRS), Malaga, Spain, May 6-9, 2014*

Veglia E, Moggio A, Pini A, Grange C, Chazot PL, **Rosa AC**. Histamine Reduces ZO-1 Tight-Junction Protein Expression in Human Immortalized Podocytes. *Queen Elizabeth II Conference Centre London Pharmacology 2014, London December 16-18, 2014*

Veglia E, Grange C, Pini A, Camussi G, Chazot PL, Fantozzi R, **Rosa AC**. Functional identification of the H4R in the human kidney. *43rd Annual Meeting of the European Histamine Research Society (EHRS), Lyon, France, May 7-10, 2014*

Veglia E, Grange C, Pini A, Camussi G, Chazot PL, **Rosa AC**. Histamine H3 receptor expression in the human kidney. *43rd Annual Meeting of the European Histamine Research Society (EHRS), Lyon, France, May 7-10, 2014*

Rosa AC, Grange C, Veglia E, Pini A, Katebe MA, Chazot PL, Fantozzi R. Histamine H4 receptor in the kidney. *Final Conference of COST Action BM0806; Advances in Histamine H4R Research, Cape Sounion, Athens, Greece 21-23 March 2013*

Rosa AC, Grange C, Pini A, Katebe MA, Benetti E, Collino M, Miglio G, Bani D, Camussi G, Chazot PL, Fantozzi R. Histamine H4 receptors are present in the kidney of diabetic rats. *European Association for the Study of Diabetes 48th Annual Meeting Berlin, Germany 1-5 October 2012*

Rosa AC, Grange C, Katebe MA, Benetti E, Collino M, Miglio G, Camussi G, Chazot PL, Fantozzi R. H₄ receptor is overexpressed in the kidney of diabetic rats *European Histamine Research Society 41st Annual Meeting held jointly with COST Action BM0806 2-5 May 2012 Belfast – Northern Ireland, UK*

Rosa AC, Rattazzi L, Miglio G, Fantozzi R. Angiotensin II promotes cytokine production in human podocytes *WorldPharma 2010 – Copenhagen, Denmark 17-23 July 2010*

Miglio G, **Rosa AC**, Rattazzi L, Fantozzi R. Nuclear receptor targets for treatment of diseases peroxisome proliferator-activated receptor (PPAR) agonists protect podocytes from human kidney against cell death induced by oxygen/glucose deprivation-reoxygenation. *WorldPharma 2010 – Copenhagen, Denmark 17-23 July 2010*

Benetti E, **Rosa AC**, Gallicchio M, Fantozzi R. Substance P-induced cyclooxygenase-2 expression in polymorphonuclear cells. *European histamine research society. XXXVI Annual Meeting – Firenze 9-12 maggio, 2007*

National conferences

Verta R, Cristina Grange C, Gurrieri M, Borga S, Nardini P, Argenziano M, Ghè C, Cavalli R, Benetti E, Miglio G, Bussolati B, Pini A, **Rosa AC**. Bilastine preserves the glomerular junctional integrity in a murine model of diabetic nephropathy. *39° Congresso Nazionale SIF - Ricerca Innovazione Sostenibilità Appropriatelyzza Formazione Farmaci, Salute e Qualità della vita, 20 - 23 November 2019, Firenze, Italy*

Rosa AC, Benetti E, Audisio J, Miglio G. Targets of dimethyl fumarate: a novel predictive method based on concepts of network theory and machine learning. *39° Congresso Nazionale SIF - Ricerca Innovazione Sostenibilità Appropriatelyzza Formazione Farmaci, Salute e Qualità della vita, 20 - 23 November 2019, Firenze, Italy*

Rosa AC, Benetti E, Audisio J, Miglio G. Ampicillin for the treatment of the early-onset neonatal infections: a pharmacometric assessment by stochastic simulations. *39° Congresso Nazionale SIF - Ricerca Innovazione Sostenibilità Appropriatelyzza Formazione Farmaci, Salute e Qualità della vita, 20 - 23 November 2019, Firenze, Italy*

Rosa AC, Pini A, Grange C, Catarinichia S, Argenziano M, Camussi G, Chazot PL, Thurmond R. Megalin and Sodium-Hydrogen Exchanger (NHE)3 modulation participate to the beneficial effect of JNJ39758979 in diabetic nephropathy *38° Congresso Nazionale SIF - Farmaci, Salute e Qualità della vita, 25 - 28 October 2017, Rimini, Italy*

Veglia E, Pini A, Moggio A, Grange C, Chazot PL, Fantozzi R, **Rosa AC**. Histamine receptor distribution along the nephron. *37° Congresso Nazionale Della Società Italiana Di Farmacologia, 27-30 October 2015, Naples Italy*

Veglia E, Pini A, Moggio A, Grange C, Chazot PL, Fantozzi R, **Rosa AC**. H1 histamine receptor affects the integrity of glomerular slit diaphragm. *37° Congresso Nazionale Della Società Italiana Di Farmacologia, 27-30 October 2015, Naples Italy*

Veglia E, Grange C, Camussi G, Chazot PL, Fantozzi R, **Rosa AC**. Histamine receptors are expressed in human kidney. *36° Congresso Nazionale Della Società Italiana Di Farmacologia, 23-26 October 2013, Turin Italy*

Luppino MR, **Rosa AC**, Casale F, Cerbai E, Fantozzi R, “SIF-Farmaci in evidenza” network. Independent drug information: the SIF Farm *34° Congresso Nazionale della Società Italiana di Farmacologia 14-17 Ottobre 2009 Rimini, Italy*

Miglio G, **Rosa AC**, Rattazzi L, Benetti E, Collino M, Fantozzi R. PPAR stimulation protects human podocytes from serum deprivation-induced cell death. *34° Congresso Nazionale della Società Italiana di Farmacologia 14-17 Ottobre 2009 Rimini, Italy*

Collino M, Benetti E, Miglio G, Castiglia S, **Rosa AC**, Thiemermann C, Fantozzi R. PPAR- β/δ activation protects against renal ischemia/reperfusion injury in diabetic rats. *34° Congresso Nazionale della Società Italiana di Farmacologia 14-17 Ottobre 2009 Rimini, Italy*

Maria Rosa Luppino MR, **Rosa AC**, Casale F, Cerbai E, Fantozzi R, SIF-Farmaci in evidenza: una nuova iniziativa della Società Italiana di Farmacologia. *XVII Seminario Nazionale La valutazione dell'uso e della sicurezza dei farmaci: esperienze in Italia -Istituto Superiore di Sanità, 15 Dicembre 2008 Rome, Italy*

Collino M, Miglio G, **Rosa AC**, Castiglia S, Rattazzi L. Modulazione farmacologica della patologia ischemica: studio degli effetti dei ligandi di PPAR. *Giornata della Ricerca, Dip. Di Anatomia, farmacologia e Medicina Legale, Università degli Studi di Torino 13 Giugno 2008 Turin Italy*

Galicchio M, **Rosa AC**, Dianzani C, Fantozzi R. Celecoxib decreases ICAM-1 and VCAM- 1 expression in HT29 cell line. *Inflammation and Cancer: International workshop 8-9 Novembre, 2007 Rozzano, Milan, Italy*

Rosa AC, Galicchio M, Dianzani C, Brucato L, Collino M, Fantozzi R. Celecoxib modulates the expression of the adhesion molecules in colon cancer cells. *33° Congresso Nazionale della Società Italiana di Farmacologia 6-9 Giugno, 2007 Cagliari Italy*

Rosa AC. Modulation of the oxidative stress and inflammatory response by Peroxisome Proliferator-Activated Receptor- γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. *IX Seminario Nazionale per Dottorandi in Farmacologia e Scienze Affini –Certosa di Pontignano, 20-23 settembre 2005 Siena Italy*

Galicchio M, Collino M, **Rosa AC**, Benetti E, Dianzani C, Fantozzi R. Substance P induces COX-2 expression in Human Umbilical Vein Endothelial Cells. *32° Congresso Nazionale della Società Italiana di Farmacologia 1-4 giugno, 2005 Naples, Italy*

Galicchio M, **Rosa AC**, Benetti E, Gaia E, Fantozzi R. Expression of COX-2, iNOS and MAPKs in colorectal adenomas. *32° Congresso Nazionale della Società Italiana di Farmacologia 1-4 giugno, 2005 Naples, Italy*

PEER-REVIEWED CONFERENCE PROCEEDINGS

Verta R, Gurrieri M, Borga S, Argenziano M, Nardini P, Cavalli R, Grange C, Pini A, **Rosa AC**. Effect of bilastine on the progression of diabetic nephropathy in DBA2/J mice. *Inflammation Research 2019; 68 (Suppl 1) S64*

Gurrieri M, Nardini P, Dell'Accio A, Ilona O, Liu S, **Rosa AC**, Pini A. CNS-sparing H3R antagonist as a candidate for the treatment of diabetes associated (gastro)intestinal symptoms. *Inflammation Research 2019; 68 (Suppl 1) S32*

Benetti E, Bordano V, Barutta F, Gruden G, Fedele C, **Rosa AC**, Klein T, Miglio G. DPP-4 release in human podocytes. *Diabetologia 2018; 61:S505*

Verta R, Pini A, Gurrieri M, Grange C, Thurmond RL, **Rosa AC**. JNJ39758979 Preserves Renal Aquaporin Expression Balance in a Model of Diabetic Nephropathy. *Inflammation Research 2018; 67 (Suppl 1) S34*

Pini A, Verta R, Grange C, Thurmond RL, **Rosa AC**. Renal Function in the H4R Knockout Mouse. *Inflammation Research* 2018; 67 (Suppl1) S34-35

Battell E, **Rosa AC**, Chazot PL, Pini A, Liu WLS, Obara I, Novel peripheral histamine H3 receptor antagonist ZPL-868087 attenuates mechanical hypersensitivity in neuropathic pain in mice. *Inflammation Research* 2017 July; 66 (Suppl1) S21-22

Rosa AC, Pini A, Obara I, Sasse A, Sanchez- Jimenez F, Stark H, Masini E, Leurs R, Chazot PL. Histamine and diabetes: where we are and where are we going. *Inflammation Research* 2017 July; 66 (Suppl1) S42

Rosa AC, Veglia E, Argenziano M, Cavalli R, Thurmond RL, Chazot PL, Pini A. A new hope for the treatment of diabetic nephropathy based on histamine H4R antagonism. *Diabetologia* 2016; 59: S486

Pini A, Veglia E, Grange C, Argenziano M, Cavalli R, Fantozzi R, Thurmond RL, Chazot PL, **Rosa AC**. JNJ 39758979 prevents the progression of diabetic nephropathy. *Inflammation Research* 2016 July; 65 (Suppl1) S39

Pini A, Chazot PL, **Rosa AC**. Parallel hierarchical intra-strain difference between the susceptibility to diabetic nephropathy and renal histamine receptor expression. *Inflammation Research* 2016 July; 65 (Suppl1) S45

Veglia E, Pini A, Moggio A, Grange C, Fantozzi R, Chazot PL, **Rosa AC**. Histamine Affects the Glomerular Slit Diaphragm Integrity Through H1R. *Inflammation Research* 2015 July; 64 (Suppl1) S41

Veglia E, Grange C, Pini A, Camussi G, Chazot PL, Fantozzi R, **Rosa AC**. Functional identification of the H4R in the human kidney. *Inflammation Research* 2014 Sep; 63 S22-23

Veglia E, Grange C, Pini A, Camussi G, Chazot PL, **Rosa AC**. Histamine H3 receptor expression in the human kidney. *Inflammation Research* 2014 Sep; 63 S13

Rosa AC, Grange C, Pini A, Katebe MA, Benetti E, Collino M, Miglio G, Bani D, Camussi G, Chazot PL, Fantozzi R. Histamine H₄ receptors are present in the kidney of diabetic rats. *Diabetologia*. 2012; 55: S459

Rosa AC, Rattazzi L, Miglio G, Fantozzi R. Angiotensin II promotes cytokine production in human podocytes *BCPT* 2010 107 (s1): 548

Miglio G, **Rosa AC**, Rattazzi L, Fantozzi R. Nuclear receptor targets for treatment of diseases peroxisome proliferator-activated receptor (PPAR) agonists protect podocytes from human kidney against cell death induced by oxygen/glucose deprivation-reoxygenation. *BCPT* 2010 107 (s1): 456